Recently, Shenzhen Mellow Hope achieved a significant milestone by successfully registering a China innovative drug, the Recombinant Human Basic Fibroblast Growth Factor for External Use ( rh-bFGF), in a country in Africa and received the registration certificate issued by the local regulatory authority. This marks a major achievement for Mellow Hope in promoting China innovative drugs internationally.
Categorized as a national first-class innovative drug, this drug is primarily indicated for the treatment of various types of wounds, including chronic wounds, fresh wounds, and burn wounds. It not only facilitates rapid wound healing but also effectively prevents scar formation and promotes functional recovery of the cell.
In many underdeveloped countries and regions in Africa, patients with wounds continues to increase due to wars, traffic accidents, diabetes and other reasons. Acute and chronic wounds bring great pain to patients, and the high cost of treatment adds a heavy financial burden to them. Mellow Hope’s successful introduction of this innovative product of high efficacy in Africa is expected to provide wound patients in African countries with a more economical and convenient treatment, while reducing the overall treatment cost and bringing great benefits to the African people.
As Chinese President Xi Jinping elaborated on the Belt and Road Initiative proposed in 2013, the joint construction of the Belt and Road aims to promote the common development of countries along the route and achieve mutual benefit and win-win results. By introducing China innovative drug, Mellow Hope actively responded to this national initiative. It not only provided efficient trauma treatment for African people, but also played an active role in promoting regional harmony and stability and improving the quality of life of local people.
Shenzhen Mellow Hope has made exciting progress on the road to registration and promotion of innovative drugs in China. The introduction of rh-bFGF to Africa once again demonstrates the commitment of our Chinese enterprises to actively respond to national policies, drive the internationalization of domestic innovative drugs, and in the end contribute to the construction of a “community with a shared future for mankind”.